A group led by Doma Perpetual Capital Management and investor Pedro Escudero has acquired nearly 2.7 million shares, or about 5.7% of Pacira Biosciences (PCRX), according to a regulatory filing on Friday.
The filing said that the purpose of the share purchases is to influence Pacira's decision-making, but there is currently no intention to take full control or initiate a merger, reorganization, or changes to management. However, the reporting parties said in the filing they reserve the right to consider such actions if the stock underperforms.
Shares of Pacira Biosciences rose past 3% in recent trading activity.
Price: 24.67, Change: +0.90, Percent Change: +3.79
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.